LON:REDX

Redx Pharma (REDX) Share Forecast, Price & News

GBX 25.50

+0.50 (+2.00%)

(As of 09/27/2023 ET)

Compare

Today's Range: 24.25
▼
26.97
50-Day Range: 22
▼
28
52-Week Range: 22
▼
70

Volume: 23,738 shs
Average Volume: 13,437 shs
Market Capitalization: £85.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Headlines

About Redx Pharma (LON:REDX) Stock

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

REDX Price History

30 days | 90 days | 365 days | Advanced Chart

REDX Stock News Headlines

September 27, 2023 | msn.com

Avalyn raises $175m in funding to develop inhaled IPF drugs

August 29, 2023 | msn.com

FDA sees potential in zelasudil for the treatment of idiopathic pulmonary fibrosis

September 27, 2023 | Behind the Markets (Ad)

6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company

Decades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>

August 21, 2023 | msn.com

MARKET REPORT: Indivior shares rise after £24m Suboxone handout

August 21, 2023 | lse.co.uk

Redx Pharma says RXC007 receives orphan drug designation from US FDA

August 21, 2023 | marketwatch.com

Redx Pharma Lung Disease Treatment Receives US FDA Orphan Drug Designation

July 10, 2023 | lse.co.uk

Redx Pharma extends term of outstanding notes with two lenders to 2024

May 17, 2023 | marketwatch.com

Redx Pharma 1H Pretax Loss Widens on Falling Revenue, Higher Costs

September 27, 2023 | Behind the Markets (Ad)

3 Words and a 3,000% Return

In October 2013, a scientist wrote 3 words on a piece of paper. They were simple words. A fiveyear-old could say them. But these three words could deliver you a 3,000% return in 2023 >>>

May 17, 2023 | lse.co.uk

Redx Pharma half-year loss doubles amid costs of failed Jounce merger

April 17, 2023 | finance.yahoo.com

Investors in Redx Pharma (LON:REDX) have made a fantastic return of 404% over the past five years

April 3, 2023 | benzinga.com

Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

March 27, 2023 | thetimes.co.uk

Redx deal fails after rival backs out

March 27, 2023 | marketwatch.com

Redx Pharma Shares Fall After Jounce Pulls Out of Merger

March 27, 2023 | msn.com

Drug developer Redx Pharma's $425m merger with Jounce Therapeutics off after takeover agreed

March 27, 2023 | finance.yahoo.com

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

March 15, 2023 | bizjournals.com

In the midst of a reverse merger, Jounce Therapeutics gets competing offer

March 15, 2023 | finanznachrichten.de

Jounce Therapeutics, Inc.: Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

March 15, 2023 | msn.com

Planned $425m merger under threat after rival's 'unsolicited' takeover bid

March 13, 2023 | finance.yahoo.com

Redx Pharma sees potential for RXC004 as a combination therapy

March 10, 2023 | thetimes.co.uk

Oxford Nanopore’s share collapse hurts IP Group

March 9, 2023 | finance.yahoo.com

Form 8.3 - REDX PHARMA PLC

March 8, 2023 | marketwatch.com

Redx Pharma Shares Dive on Cancer-Treatment Study Results

February 23, 2023 | thetimes.co.uk

Redx Pharma to abandon London for New York

February 23, 2023 | finance.yahoo.com

Why Jounce Therapeutics Shares Are Trading Higher Today

February 23, 2023 | finance.yahoo.com

Biotech firms Redx Pharma and Jounce Therapeutics to combine business

February 23, 2023 | marketwatch.com

Shares in Redx Pharma Rise on Jounce Therapeutics Merger

See More Headlines

Receive REDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter.

REDX Company Calendar

Last Earnings: 11/19/2018
Today: 9/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:REDX
CUSIP: N/A
CIK: N/A
Web: redxpharma.com
Phone: +44-151-7064747
Fax: N/A
Employees: 95
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-29,010,000.00
Net Margins: -229.35%
Pretax Margin: N/A
Return on Equity: -285.71%
Return on Assets: -40.66%

Debt

Debt-to-Equity Ratio: 125.92
Current Ratio: 1.52
Quick Ratio: 1.93

Sales & Book Value

Annual Sales: £12.65 million
Price / Sales: 6.52
Cash Flow: GBX 4.71 per share
Price / Cash Flow: 5.23
Book Value: GBX 5 per share
Price / Book: 4.93

Miscellaneous

Outstanding Shares: 334,910,000
Free Float: N/A
Market Cap: £82.54 million
Optionable: Not Optionable
Beta: -0.27

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Ms. Lisa Mary Whewell Anson (Age 53)
CEO & Exec. Director
Comp: $636.99k

Mr. Peter J. Collum
Chief Financial Officer

Dr. James Mead (Age 45)
Chief Operating Officer

Dr. Richard Armer
Chief Scientific Officer

Dr. Karl Hard Ph.D. (Age 61)
Head of Investor Relations

Ms. Claire Solk
Gen. Counsel & Company Sec.

Ms. Caitlin Pearson
Head of Communications

Dr. Jane Robertson
Chief Medical Officer

Dr. Cliff Jones
Sr. VP of Chemistry, DMPK & Intellectual Property

Dr. Caroline Phillips
Sr. VP of Biology

Key Competitors

View All Competitors

REDX Stock - Frequently Asked Questions

How have REDX shares performed in 2023?: Redx Pharma's stock was trading at GBX 64.50 at the beginning of 2023. Since then, REDX shares have decreased by 61.8% and is now trading at GBX 24.65.
View the best growth stocks for 2023 here.
How were Redx Pharma's earnings last quarter?: Redx Pharma Plc (LON:REDX) issued its quarterly earnings data on Monday, November, 19th. The company reported ($7.00) earnings per share for the quarter, missing the consensus estimate of ($6.50) by $0.50. Redx Pharma had a negative trailing twelve-month return on equity of 285.71% and a negative net margin of 229.35%.
What other stocks do shareholders of Redx Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Redx Pharma investors own include Digital Globe Services (DGS), OptiBiotix Health (OPTI), TLA Worldwide (TLA), Be Heard Group plc (BHRD.L) (BHRD), Salesforce (CRM), Carnival Co. & (CCL), Burberry Group (BRBY), boohoo group (BOO) and Bank of New York Mellon (BK).
What is Redx Pharma's stock symbol?: Redx Pharma trades on the London Stock Exchange (LON) under the ticker symbol "REDX."

How do I buy shares of Redx Pharma?: Shares of REDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Redx Pharma's stock price today?: One share of REDX stock can currently be purchased for approximately GBX 24.65.
How much money does Redx Pharma make?: Redx Pharma (LON:REDX) has a market capitalization of £82.54 million and generates £12.65 million in revenue each year. The company earns £-29,010,000.00 in net income (profit) each year or GBX (0.09) on an earnings per share basis.
How can I contact Redx Pharma?: Redx Pharma's mailing address is Block 33, Mereside,, Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom. The official website for the company is redxpharma.com. The company can be reached via phone at +44-151-7064747.

This page (LON:REDX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial